MISSION VIEJO, Calif., July 14, 2017 (GLOBE NEWSWIRE) — MYnd Analytics, Inc. (Nasdaq:MYND), a predictive analytics company which brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing, announced today the pricing of its firm commitment underwritten public offering of 1,675,000 shares of its common stock and accompanying warrants to purchase up to 1,675,000 shares of its common stock, at a combined public offering price of $5.25 per share and accompanying warrant, for a total offering size of $8,793,750. The warrants will be immediately exercisable for one share of common stock at an exercise price of $5.25 per share, subject to adjustments, and will expire five years after the issuance date.The shares of common stock and warrants can only be purchased together in the offering but will be immediately separable upon issuance.All of the shares of common stock and warrants in the offering are being sold by MYnd Analytics, Inc.The common stock and warrants have been approved for listing on The Nasdaq Capital Market and will begin trading thereon under the symbols “MYND” and “MYNDW”, respectively, at the opening of trading on Friday, July 14, 2017.

In addition, MYnd has granted the underwriters of the offering a 45-day option to purchase up to an additional 251,250 shares of common stock and/or warrants at the public offering price less the underwriting discount, solely to cover over-allotments, if any.The offering is expected to close on Wednesday, July 19, 2017, subject to customary closing conditions. 

Maxim Group LLC and Aegis Capital Corp. are acting as joint book-running managers, and R.F. Lafferty & Co., Inc. is acting as co-manager for the offering.

MYnd expects to receive net proceeds from the offering, after deducting underwriting discounts and commissions and other expenses payable by it, of approximately $7.75 million. 

The shares are being offered pursuant to a registration statement on Form S-1, as amended, previously filed with the Securities and Exchange Commission (SEC).A preliminary prospectus related to the offering was filed with the SEC on June 30, 2017. The final prospectus will be filed with the SEC.When available, copies of the final prospectus relating to this offering may also be obtained by contacting Maxim Group LLC, 405 Lexington Ave., New York, NY, 10174; Attn: Prospectus Department, or by Telephone: (800) 724-0761; or Email: [email protected], or by accessing the SEC’s website at www.sec.gov.